This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.
Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.
Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.
Shattuck Labs (STTK) is the sponsoring company for this trial. BiotechSign currently grades this company D (45/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.